Tag
The phase 2 MIRA trial shows sonelokimab, an IL-17A/F-inhibiting nanobody, significantly improves outcomes in moderate-to-severe hidradenitis suppurativa with good tolerability compared to placebo.
This review synthesizes current evidence on adalimumab, secukinumab, and bimekizumab for moderate-to-severe hidradenitis suppurativa, emphasizing clinical efficacy, safety, mechanistic insights, and cost-effectiveness across diverse health
This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients
The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therap
This review synthesizes the 52-week pooled results from two Phase 3 trials, detailing the pharmacokinetics, safety, and biomarker responses of secukinumab in moderate-to-severe hidradenitis suppurativa.
A Phase 2 trial of eltrekibart, a novel monoclonal antibody targeting CXCR1/2 ligands, suggests high clinical efficacy in hidradenitis suppurativa. While frequentist analysis was neutral, Bayesian augmented models showed a 99.9% probability
This systematic review and meta-analysis evaluates 15 HS-specific PROMs using the COSMIN framework, identifying 7 recommended instruments and highlighting the superior psychometric performance of HiSQOL-17 while uncovering significant gaps
Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemi
An international Delphi consensus produced standardized morphological definitions and practical guidance to improve investigator lesion assessment in hidradenitis suppurativa clinical trials, enhancing reliability and trial data quality.
A multidisciplinary Delphi panel produced consensus morphological definitions and practical guidance to standardize investigator lesion assessments in hidradenitis suppurativa (HS) clinical trials — improving reliability of endpoints such a
This living systematic review and network meta-analysis evaluates efficacy, safety, and tolerability of medical treatments for moderate to severe hidradenitis suppurativa, highlighting top-performing agents and informing clinical decision-m
Patients with hidradenitis suppurativa face a higher risk of first-time depression and anxiety, regardless of disease severity, highlighting the need for comprehensive psychiatric care.
Patients with hidradenitis suppurativa face a significantly increased risk of new-onset depression and anxiety, independent of disease severity, highlighting the need for universal psychiatric assessment in this population.
